Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prostate cancer screening - is it time to change approach

M. Vargovčák, E. Dorko, K. Rimárová, V. Knap

. 2022 ; 30 (Suppl.) : S11-S15. [pub] -

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22033982

Digitální knihovna NLK
Zdroj

E-zdroje Online Plný text

NLK Free Medical Journals od 2004
ProQuest Central od 2009-03-01 do Před 6 měsíci
Medline Complete (EBSCOhost) od 2006-03-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest) od 2009-03-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 2009-03-01 do Před 6 měsíci
Public Health Database (ProQuest) od 2009-03-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources od 1993

OBJECTIVE: Prostate adenocarcinoma (CaP) is one of the most common malignancies in men in Slovakia and in the world. The disease accounts for more than 22% of all tumors in the male population. Screening studies show an increase in the diagnosis of CaP without improvement in overall or CaP-specific mortality. The main goal of the work is to evaluate the incidence of CaP in the group of patients examined and treated during the period from 2014 to 2019 at the urological outpatient clinic of the Railway Hospital (RH) in Košice, and to evaluate the risks and treatment options. METHODS: Men aged 40 to 75 years underwent a preventive examination in 2014-2019 at the urology outpatient clinic, RH Košice. The number of screened patients was 3,943. Epidemiological parameter, diagnosis-related examinations (prostate specific antigen - PSA examination, digital rectal examination, and ultrasonography examination) as well as the frequency of examinations were monitored during the specified period on the basis of documentation. The number of prostate biopsies, incidence of prostate cancer and relation to PSA values were also monitored, as well as the classification of prostate cancers according to the degree of risk. Initial treatment in individual patients was also evaluated. RESULTS: PSA values in patients who underwent biopsy ranged from 3.6 ng/mL to 2,000 ng/mL. We observed positive digital rectal examination in 52 patients. Of the number of patients examined, 231 (61.28%) were positive biopsies. There were negative biopsies with the finding of benign prostatic hyperplasia in 92 patients or chronic prostatitis in 54 patients, i.e., 146 (38.72%). According to the criteria for risk assessment based on the PSA value and the result of the histological examination, we diagnosed 109 low-risk patients, 57 medium-risk patients and 24 high-risk patients. CONCLUSION: CaP is detected by prevention about 10 years before it develops clinically. The main aim of preventive examinations should be to detect, in particular, high-risk forms of early-stage prostate cancer and to improve the quality of life of men. Due to the results of extensive studies, it is necessary to continue the active search for prostate cancer. This reduces the risk of metastatic forms of CaP.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033982
003      
CZ-PrNML
005      
20230313133845.0
007      
ta
008      
230207s2022 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.21101/cejph.a6807 $2 doi
035    __
$a (PubMed)35841219
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Vargovčák, Marek, $d 1975- $u Urological Outpatient Clinic, Railway Hospital, Kosice, Slovak Republic $7 xx0283270
245    10
$a Prostate cancer screening - is it time to change approach / $c M. Vargovčák, E. Dorko, K. Rimárová, V. Knap
520    9_
$a OBJECTIVE: Prostate adenocarcinoma (CaP) is one of the most common malignancies in men in Slovakia and in the world. The disease accounts for more than 22% of all tumors in the male population. Screening studies show an increase in the diagnosis of CaP without improvement in overall or CaP-specific mortality. The main goal of the work is to evaluate the incidence of CaP in the group of patients examined and treated during the period from 2014 to 2019 at the urological outpatient clinic of the Railway Hospital (RH) in Košice, and to evaluate the risks and treatment options. METHODS: Men aged 40 to 75 years underwent a preventive examination in 2014-2019 at the urology outpatient clinic, RH Košice. The number of screened patients was 3,943. Epidemiological parameter, diagnosis-related examinations (prostate specific antigen - PSA examination, digital rectal examination, and ultrasonography examination) as well as the frequency of examinations were monitored during the specified period on the basis of documentation. The number of prostate biopsies, incidence of prostate cancer and relation to PSA values were also monitored, as well as the classification of prostate cancers according to the degree of risk. Initial treatment in individual patients was also evaluated. RESULTS: PSA values in patients who underwent biopsy ranged from 3.6 ng/mL to 2,000 ng/mL. We observed positive digital rectal examination in 52 patients. Of the number of patients examined, 231 (61.28%) were positive biopsies. There were negative biopsies with the finding of benign prostatic hyperplasia in 92 patients or chronic prostatitis in 54 patients, i.e., 146 (38.72%). According to the criteria for risk assessment based on the PSA value and the result of the histological examination, we diagnosed 109 low-risk patients, 57 medium-risk patients and 24 high-risk patients. CONCLUSION: CaP is detected by prevention about 10 years before it develops clinically. The main aim of preventive examinations should be to detect, in particular, high-risk forms of early-stage prostate cancer and to improve the quality of life of men. Due to the results of extensive studies, it is necessary to continue the active search for prostate cancer. This reduces the risk of metastatic forms of CaP.
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prostata $x patologie $7 D011467
650    12
$a prostatický specifický antigen $7 D017430
650    12
$a nádory prostaty $x diagnóza $x epidemiologie $7 D011471
650    _2
$a kvalita života $7 D011788
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dorko, Erik $u Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0063738
700    1_
$a Rimárová, Kvetoslava, $u Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $d 1958- $7 xx0224806
700    1_
$a Knap, Viliam, $d 1974- $u Department of Physiatry, Balneology, and Medical Rehabilitation, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0283272
773    0_
$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 30, Suppl. (2022), s. S11-S15
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35841219 $y Pubmed
910    __
$a ABA008 $b B 1829 $c 562 $y p $z 0
990    __
$a 20230207 $b ABA008
991    __
$a 20230313133843 $b ABA008
999    __
$a ok $b bmc $g 1896173 $s 1185371
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 30 $c Suppl. $d S11-S15 $e - $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083
LZP    __
$b NLK198 $a Pubmed-20230207

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...